Orisilogenomics
A pioneer in cell-free synthesis and amplification of genome-scale large DNA for synthetic biology.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD116m (Public information from Jan 2023)
Tokyo Japan (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | JPY3.0m | Early VC | |
$3.6m | Series A | ||
JPY800m | Series B | ||
JPY200m | Debt | ||
* | N/A | Series B | |
* | $85.0m Valuation: $85.0m | Acquisition | |
| Total Funding | CAD13.3m | ||
Related Content
Recent News about Orisilogenomics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.